Generic placeholder image

Current Cardiology Reviews


ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Case Report

Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome

Author(s): Ayman Battisha*, Khalid Sawalha, Bader Madoukh, Omar Sheikh, Karim Doughem, Mohammad Al-Akchar, Mohammed Al-Sadawi and Shakil Shaikh

Volume 16, Issue 4, 2020

Page: [333 - 337] Pages: 5

DOI: 10.2174/1573403X16666200331123242

Price: $65


Background: Systemic Mastocytosis (SM) is a disorder of excessive mast cell infiltration in multiple organ tissues. Atherosclerosis is a major risk factor for developing acute coronary syndrome. In addition to lipid accumulation in the arterial wall, inflammation plays an important role in the pathogenesis of plaque rupture and activating the thrombosis cascade. The Mast cells contribution to plaque destabilization has been well established in multiple animal and human studies. In a recent study, SM has been proven to be associated with a higher incidence of acute coronary syndrome even with lower plasma lipids levels. The study showed that 20% of patients with SM had cardiovascular events compared to only 6% in the control group with adjustment to all cardiac risk factors.

Case: We presented a patient with no risk factors for heart disease other than old age and history of SM who developed acute myocardial infarction.

Conclusion: SM can be life-threatening and can result in ACS, anaphylactic reaction, syncope, or cardiac arrest. Clinicians should have a high index of suspicion of acute coronary syndrome (ACS) occurrence in the setting of inflammatory conditions, such as SM and KS, and vice versa, where SM should be considered or ruled out in patients who suffer from anaphylaxis and cardiac arrest or myocardial infarction.

Keywords: SM, electrocardiogram, subclinical hypothyroidism, patient, myocardial infarction, acute coronary syndrome.

Graphical Abstract
Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41(4)(Suppl. S): 15S-22S.
[ PMID: 12644336]
Stoll G, Bendszus M. Inflammation and atherosclerosis: Novel insights into plaque formation and destabilization. Stroke 2006; 37(7): 1923-32.
[ PMID: 16741184]
Lagraauw HM, Wezel A, van der Velden D, Kuiper J, Bot I. Stress-induced mast cell activation contributes to atherosclerotic plaque destabilization. Sci Rep 2019; 9(1): 2134.
[ PMID: 30765859]
Indhirajanti S, van Daele PLA, Bos S, Mulder MT, Bot I, Roeters van Lennep JE. Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. Atherosclerosis 2018; 268: 152-6.
[ PMID: 29227868]
Paratz ED, Khav N, Burns AT. Systemic mastocytosis, Kounis syndrome and coronary intervention: Case report and systematic review. Heart Lung Circ 2017; 26(8): 772-8.
[ PMID: 28242292]
Hermans M, Lennep JRV, van Daele P, Bot I. Mast cells in cardiovascular disease: From bench to bedside. Int J Mol Sci 2019; 20(14): 3395.
[ PMID: 31295950]
Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. Am J Hematol 2016; 91(11): 1069-75.
[ PMID: 27428296]
Bot I, Shi GP, Kovanen PT. Mast cells as effectors in atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35(2): 265-71.
[ PMID: 25104798]
Niccoli G, Montone RA, Sabato V, Crea F. Role of allergic inflammatory cells in coronary artery disease. Circulation 2018; 138(16): 1736-48.
[ PMID: 30354461]
Huang A L, Bosco J J, Peter K. Mast cell: An unexpected villain in venous thromboembolism? 2017; 121(8): 899-901.
[] [PMID: 28963183]
Erdogan O, Altun A, Gazi S, Ozbay G. Loratidine improves ischemic parameters of exercise stress test in patients with acute myocardial infarction. Am Heart J 2004; 148(6)e24
[ PMID: 15632861]
Ridolo E, Triggiani M, Montagni M, et al. Mastocytosis presenting as cardiac emergency. Intern Emerg Med 2013; 8(8): 749-52.
[ PMID: 24136074]
Rohr SM, Rich MW, Silver KH. Shortness of breath, syncope, and cardiac arrest caused by systemic mastocytosis. Ann Emerg Med 2005; 45(6): 592-4.
[ PMID: 15940090]
Thomas D, Dragodanne C, Frank R, Prier A, Chomette G, Grosgogeat Y. Systemic mastocytosis with myo-pericardial localization and atrioventricular block. Arch Mal Coeur Vaiss 1981; 74(2): 215-21.
[PMID: 6782979]
Kounis NG. Coronary hypersensitivity disorder: The Kounis syndrome. Clin Ther 2013; 35(5): 563-71.
[ PMID: 23490289]
Rigger J, Ehl NF, Nägele R, Rickli H, Maeder MT. Kounis syndrome revisited: Systemic mastocytosis and severe coronary artery disease. Int J Cardiol 2016; 214: 510-1.
[ PMID: 27040990]
Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90(4): 1669-78.
[ PMID: 7923651]
Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119-31.
[ PMID: 28845751]
James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108(3): 275-81.
[ PMID: 12847065]
Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107(13): 1750-6.
[ PMID: 12665489]
Berwanger O, Santucci EV, de Barros E, Silva PGM, et al. SECURE-PCI Investigators Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. JAMA 2018; 319(13): 1331-40.
[ PMID: 29525821]
Husebye T, Eritsland J, Arnesen H, et al. Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure. PLoS One 2014; 9(11)e112359
[ PMID: 25390695]
Limalanathan S, Andersen GØ, Hoffmann P, Kløw NE, Abdelnoor M, Eritsland J. Rationale and design of the POSTEMI (postconditioning in ST-elevation myocardial infarction) study. Cardiology 2010; 116(2): 103-9.
[ PMID: 20588018]
Rymer JA, Newby LK. Failure to launch: Targeting inflammation in acute coronary syndromes. JACC Basic Transl Sci 2017; 2(4): 484-97.
[ PMID: 30062164]
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381(26): 2497-505.
[ PMID: 31733140]
Ridker PM, Everett BM, Pradhan A, et al. CIRT Investigators Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380(8): 752-62.
[ PMID: 30415610]
Fiedler LR. Antibody based therapy in coronary artery disease and heart failure. Heart Res Open J 2017; 4(2): 39-45.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy